Nikko Asset Management Americas Inc. Has $108.07 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Nikko Asset Management Americas Inc. cut its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,745,676 shares of the company's stock after selling 221,543 shares during the period. CRISPR Therapeutics accounts for approximately 1.2% of Nikko Asset Management Americas Inc.'s holdings, making the stock its 25th biggest holding. Nikko Asset Management Americas Inc. owned about 3.22% of CRISPR Therapeutics worth $108,070,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. ARK Investment Management LLC boosted its stake in CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. State Street Corp lifted its stake in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after purchasing an additional 599,304 shares during the period. FMR LLC grew its stake in shares of CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company's stock worth $111,632,000 after purchasing an additional 23,075 shares during the period. Geode Capital Management LLC increased its holdings in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock valued at $47,383,000 after purchasing an additional 35,196 shares during the last quarter. Finally, Baker BROS. Advisors LP lifted its stake in CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock valued at $39,608,000 after buying an additional 743,075 shares during the period. Institutional investors own 69.20% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CRSP shares. Bank of America decreased their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a report on Friday, February 14th. Royal Bank of Canada decreased their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a report on Wednesday, February 12th. Finally, Barclays raised their price objective on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Hold" and a consensus price target of $73.11.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded up $0.05 during trading hours on Friday, hitting $41.22. 1,539,000 shares of the company traded hands, compared to its average volume of 1,525,693. The business's 50-day moving average is $43.06 and its 200-day moving average is $45.41. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of -9.43 and a beta of 1.76. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock worth $1,608,243 in the last ninety days. Insiders own 4.10% of the company's stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.